Illumina, Inc. (ILMN) News
Filter ILMN News Items
ILMN News Results
|Loading, please wait...|
ILMN News Highlights
- 500 - Internal server error
- Over the past 25 days, the trend for ILMN's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
- The most mentioned tickers in articles about ILMN are GENE, PACB and BDX.
Latest ILMN News From Around the Web
Below are the latest news stories about Illumina Inc that investors may wish to consider to help them evaluate ILMN as an investment opportunity.
These healthcare stocks are at the forefront of huge trends, including precision medicine and advances in diagnosis technologies.
Are you looking for stocks that have been beaten up in recent weeks?
Photo by Georgejason/iStock Editorial via Getty Images Illumina ([[ILMN]] +3.7%) is soaring in reaction to the data announced by the cancer startup GRAIL for Galleri, a multi-cancer early detection ((MCED)) blood test. Illumina has signed an agreement to acquire GRAIL in a deal valued at $7.1B. The first results from...
About 8% of our genetic instructions remained untouched even after the sequencing project officially ended. The accomplishment is thanks in large part to new sequencing technology from Pacific Biosciences of California (NASDAQ: PACB). The initial project relied on sequencers like those made by Illumina (NASDAQ: ILMN), which reassemble short fragments of DNA after cutting them up and decoding them.
The private cancer testing firm Grail said early Friday that it had begun selling its multi-cancer blood test in the U.S.
In hindsight, the pandemic may have been that turning point for gene-based medicine. The authorization of the first vaccines using messenger RNA validated a segment of the life sciences industry that seemed destined for some futuristic version of healthcare. Genome sequencing and gene editing have been around for several years.
The broad conditions for equity buyers remain in place. Easy central bank monetary policy and broad fiscal stimulus mean conditions are suitable for f
Illumina (NASDAQ: ILMN ) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months…
Illumina's (ILMN) VeriSeq NIPT Solution v2 provides accurate, consistent and scalable end-to-end genome-wide noninvasive prenatal testing.
Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis
Illumina and BeSolveRD will study the clinical utility and health economic impact of WGS of patients with intellectual disabilities.